Effects of long-term treatment with warfarin on fibrinogen, FPA, TAT, and D-dimer in patients with coronary artery disease

Thromb Res. 1992 Apr 1;66(1):55-60. doi: 10.1016/0049-3848(92)90155-4.

Abstract

Sixty-four patients undergoing aorto-coronary bypass surgery were randomized to receive antithrombotic treatment with acetylsalicylic acid (ASA), 300 mg/d (n = 30) or warfarin, INR = 2.5 - 4.2 (n = 34). The levels of fibrinogen, thrombin-antithrombin III complexes (TAT), fibrinopeptide A (FPA) and D-dimer were assessed before surgery and 9 months postoperatively. In the warfarin treated group the fibrinogen levels were increased after 9 months, while the levels of TAT, FPA and D-dimer were decreased. In the ASA group TAT levels were increased at 9 months, whereas no significant changes in fibrinogen, FPA or D-dimer from baseline were noted. Thus, a reduced activation of the coagulation system has been demonstrated during long-term treatment with warfarin in patients with coronary artery disease.

Publication types

  • Clinical Trial
  • Randomized Controlled Trial

MeSH terms

  • Adult
  • Aged
  • Antithrombin III / metabolism*
  • Combined Modality Therapy
  • Coronary Artery Bypass
  • Coronary Disease / blood
  • Coronary Disease / drug therapy*
  • Coronary Disease / surgery
  • Fibrin Fibrinogen Degradation Products / metabolism*
  • Fibrinogen / metabolism*
  • Fibrinopeptide A / metabolism*
  • Follow-Up Studies
  • Humans
  • Middle Aged
  • Peptide Hydrolases / metabolism*
  • Time Factors
  • Warfarin / administration & dosage*

Substances

  • Fibrin Fibrinogen Degradation Products
  • antithrombin III-protease complex
  • fibrin fragment D
  • Fibrinopeptide A
  • Warfarin
  • Antithrombin III
  • Fibrinogen
  • Peptide Hydrolases